Vedanta Biosciences is creating a new class of drugs to modulate the human microbiome. Vedanta is pioneering the rational design of drugs made of defined consortia of bacteria that are essential dwellers of the gut ecosystem that perform critical functions that preserve our health including modulating our immune system and providing colonization resistance against infectious pathogens. The foundation invested in the company to develop new interventions and therapeutics based on bacterial consortia for the treatment of enteric disease and childhood stunting in the developing world.